PPC
FOLD

Park Place Capital’s Amicus Therapeutics FOLD Stock Holding History

Park Place Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-61
Closed -$564 – 843
2024
Q4 		$575 Hold
61
– – ﹤0.01% 797
2024
Q3 		$651 Hold
61
– – ﹤0.01% 843
2024
Q2 		$605 Hold
61
– – ﹤0.01% 847
2024
Q1 		$719 Hold
61
– – ﹤0.01% 889
2023
Q4 		$866 Sell
61
-90
-60% -$1.02K ﹤0.01% 834
2023
Q3 		$1.84K Hold
151
– – ﹤0.01% 931
2023
Q2 		$1.9K Hold
151
– – ﹤0.01% 945
2023
Q1 		$1.68K Hold
151
– – ﹤0.01% 962
2022
Q4 		$2K Buy
+151
New +$1.7K ﹤0.01% 948

Other funds holding FOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Park Place Capital's FOLD Position: Q1 2025 in Review

Park Place Capital sold out of Amicus Therapeutics (FOLD) in Q1 2025, closing a stake of 61 shares — an estimated $564 sold.

Park Place Capital first reported a position in FOLD in Q4 2022 and held it in 9 quarters. The position peaked at $2K in Q4 2022. 286 funds tracked by Wall St. Rank hold FOLD as of Q1 2025.

  • Park Place Capital reported no remaining Amicus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Park Place Capital sold 61 Amicus Therapeutics shares in Q1 2025, an estimated $564.
  • Park Place Capital first reported a position in Amicus Therapeutics in Q4 2022 and held it in 9 quarters.
  • Park Place Capital's Amicus Therapeutics position peaked at $2K in Q4 2022.
  • 286 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2025.

Based on Park Place Capital's 13F filing for Q1 2025, filed 24 Apr 2025.